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Abstract
Chronic obstructive pulmonary disease (COPD) is among the major health burdens in adults. While cigarette smoking is the
leading risk factor, a growing number of genetic variations have been discovered to influence disease susceptibility.
Epigenetic modifications may mediate the response of the genome to smoking and regulate gene expression. Chromosome
19q13.2 region is associated with both smoking and COPD, yet its functional role is unclear. Our study aimed to determine
whether rs7937 (RAB4B, EGLN2), a top genetic variant in 19q13.2 region identified in genome-wide association studies of
COPD, is associated with differential DNA methylation in blood (N¼1490) and gene expression in blood (N¼721) and lungs
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(N¼1087). We combined genetic and epigenetic data from the Rotterdam Study (RS) to perform the epigenome-wide associa-
tion analysis of rs7937. Further, we used genetic and transcriptomic data from blood (RS) and from lung tissue (Lung expres-
sion quantitative trait loci mapping study), to perform the transcriptome-wide association study of rs7937. Rs7937 was signifi-
cantly (FDR<0.05) and consistently associated with differential DNA methylation in blood at 4 CpG sites in cis, independent
of smoking. One methylation site (cg11298343-EGLN2) was also associated with COPD (P¼0.001). Additionally, rs7937 was
associated with gene expression levels in blood in cis (EGLN2), 42% mediated through cg11298343, and in lung tissue, in cis
and trans (NUMBL, EGLN2, DNMT3A, LOC101929709 and PAK2). Our results suggest that changes of DNA methylation and gene
expression may be intermediate steps between genetic variants and COPD, but further causal studies in lung tissue should
confirm this hypothesis.
Introduction
Chronic obstructive pulmonary disease (COPD) is a common, sys-
temic, lung disease, mainly characterized by airway obstruction
and inflammation (1). COPD often develops as a response to
chronic exposure to cigarette smoke, fumes and gases (2,3). There
is significant inter-individual variability in the response to these
environmental exposures (4,5) that has been attributed to genetic
factors (6,7). Genome-wide association studies (GWAS) have iden-
tified genetic variants associated with COPD susceptibility on
chromosomes 4q31, 4q22, 15q25 and 19q13 (8–11). However, the
mechanism explaining how these variants are involved in the
pathogenesis of COPD remains elusive (12).
As is the case for many complex diseases, many single
nucleotide polymorphisms (SNPs) associated with COPD and
lung function by GWAS are located in non-protein coding inter-
genic and intronic regulatory regions (13,14). It has been
hypothesized that these SNPs may modulate regulatory mecha-
nisms, such as RNA expression, splicing, transcription factor
binding and epigenetic modifications (e.g. DNA methylation).
Changes in RNA expression as well as in DNA methylation regu-
lating expression have recently been associated with COPD,
suggesting that genetic and epigenetic factors are working in
concert in the pathogenesis of COPD (15,16). Emerging evidence
suggests that differential methylation sites (CpGs) are poten-
tially important for COPD susceptibility (15–17), but their loca-
tion was not linked to the GWAS loci. However, important
associations in COPD genomic regions may have been missed
as arrays with limited coverage (27K) were used in the studies
conducted to date.
The 19q13.2 region is associated with COPD and cigarette
smoking (18,19), lung function (20) and emphysema patterns
(21). Genes in this region include RAB4B (member RAS oncogene
family), EGLN2 (Egl-nine homolog 2), MIA (melanoma inhibitory
activity) and CYP2A6 (cytochrome P450 family 2 subfamily
A member 6). The top variant in the region, rs7937:C>T, has
been identified by Cho et al. (9). This SNP (RAB4B, EGLN2) was
associated with COPD (OR¼ 1.37, P¼ 2.9 109), but not with
smoking. Nevertheless, in a study of 10 healthy non-smokers
and 7 healthy smokers, EGLN2 was found to be expressed at a
higher level in airway epithelium of smokers compared with
non-smokers (22). In this small, underpowered study of airway
epithelial DNA, there was no significant evidence for differential
DNA methylation of EGLN2 between smokers and non-smokers.
In this study, we set out to determine whether rs7937 is
involved in regulatory mechanisms like DNA methylation and
gene expression and whether these mechanisms are also
associated with COPD. We further evaluated the role of smok-
ing in these regulatory mechanisms. For that purpose, we per-
formed an epigenome-wide association study (EWAS) of
rs7937 in blood using an array with high coverage (450K) and a
transcriptome-wide association study of rs7937 in blood and
lung tissues.
Results
Our discovery cohort comprised 724 participants with genotype
and DNA methylation data, while the replication cohort com-
prised 766 participants from the Rotterdam Study (RS) (23).
The summary statistics of the discovery and replication cohorts
are shown in Table 1. As expected, the prevalence of males,
smokers and the average pack-years of smoking were higher in
cases, compared with controls. Compared with the replication
cohort, participants in the discovery cohort were on average 8
years younger and included significantly more COPD cases and
current smokers, although the pack-years of smoking were
comparable. The overview of the analysis pipeline and sample
sizes used is presented in Figure 1.
Methylation quantitative trait locus analysis
In the genome-wide blood methylation quantitative trait locus
(meQTL) analysis of rs7937 in the discovery cohort, rs7937 was
significantly [False Discovery Rate (FDR)<0.05] associated with
differential DNA methylation at 6 CpG sites in the genes ITPKC
and EGLN2, located within the same 19q13.2 region (Model 1,
Table 2, Fig. 2A). Five of the six methylation sites were available
in the replication dataset and four were significantly replicated
with the same direction as found in the discovery cohort
(Table 2, Figs 2B and 3). Adding smoking as a confounder
(Model 2, Table 2) and testing interaction with smoking (Model
3, data not shown) did not change the results, suggesting that
the association between rs7937 and DNA methylation at these
sites is independent of smoking. In an additional Model 4, we
show that adding COPD to the model did not change the effect
of rs7937 on DNA methylation (Supplementary Material,
Table S1).
COPD and FEV1/FVC analyses
When testing for association of DNA methylation at the four
replicated differentially methylated CpG sites with COPD, we
observed a significant association with cg11298343 (EGLN2) in
Model 1 [b (SE)¼7.080 (2.16), P¼ 0.001] (Table 3, Supplementary
Material, Table S2), which remained nominally significant with
diminished but still strong and concordant negative effect, after
adjusting for smoking [Model 2; b (SE) ¼ 4.924 (2.25), P¼ 0.029].
Further, we show that additionally adjusting for rs7937 slightly
deteriorated the effect of cg11298343 on COPD (Model 4;
Supplementary Material, Table S1).
In the association with the quantitative determinant of COPD
(Table 3, Supplementary Material, Table S2), the ratio of forced
397Human Molecular Genetics, 2018, Vol. 27, No. 2 |
Downloaded from https://academic.oup.com/hmg/article-abstract/27/2/396/4575133
by Erasmus Universiteit Rotterdam user
on 02 March 2018
expiratory volume in 1 s (FEV1) over the forced vital capacity
(FVC), we observed nominal significance for the same site [Model
1; b (SE)¼0.138 (0.07), P¼ 0.04], which deteriorated with adjusting
for smoking [Model 2; b (SE)¼0.047 (0.06), P¼ 0.46].
Blood and lung expression quantitative trait
loci analysis
In the genome-wide blood expression quantitative trait loci
(eQTL) analysis in RS, rs7937 was significantly associated with
Figure 1. Analysis pipeline and datasets overview.
Table 1. Characteristics of the discovery and replication cohorts and per COPD status
Discovery cohort Replication cohort
COPD Controls All COPD Controls All
N (% of all) 114 (15.7)a 541 (74.7) 724 93 (12.1)a 591 (77.2) 766
Age (years)a 61.968.6 59.367.9 59.968.2 68.265.7 67.665.9 67.765.9
Males (%) 68 (59.6) 233 (43.1) 331 (45.7) 54 (58.1) 249 (42.1) 324 (42.3)
FEV1/FVC(% of all) 0.6360.07(71.9) 0.7860.04(66.0) 0.7660.08(67.0) 0.6360.07(95.7) 0.7960.05(91.0) 0.7660.08(91.8)
Current smokers, n (%)a 43 (37.7) 107 (19.8) 168 (23.2) 20 (21.5) 52 (8.8) 80 (10.4)
Ex-smokers, n (%) 55 (48.2) 239 (44.2) 322 (44.5) 51 (54.8) 326 (55.2) 427 (55.7)
Never smokers, n (%) 16 (14.0) 195 (36.0) 234 (32.3) 22 (23.7) 213 (36.0) 259 (33.8)
Pack-yearsb 34.3626.9 19.9619.6 23.2622.0 33.7618.7 19.6620.1 21.9620.6
Data for quantitative measures presented as mean6SD. COPD: Chronic Obstructive Pulmonary Disease cases; All: all participants included in EWAS. For traits that
were not available for all participants (COPD status and FEV1/FVC), the valid percentage is denoted in brackets (% of all).
aSignificantly different between the discovery and replication cohort.
bPack-years data were available for all participants (mean and SD calculated in current and ex-smokers only).
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differential expression of the ILMN_2354391 probe in the EGLN2
gene [b (SE)¼0.064 (0.01), P¼ 9.3 109], (Table 4). The risk allele
(T) was associated with increased expression of EGLN2
(Supplementary Material, Fig. S1). The association signal
dropped albeit remained significant [b (SE)¼0.058 (0.01),
P¼ 1.9 106] after adjusting for the top CpG site cg11298343 in
the same gene (Table 4). This suggests that differential DNA
methylation at cg11298343 is partly responsible for the
Table 2. Association of rs7937-T with epigenome-wide DNA methylation in discovery (N¼ 724) and replication (N¼ 766) cohorts
Discovery Replication
CpG Chr Position Gene Model b SE P FDR b SE P FDR
cg21653913 19 41307778 EGLN2 1 0.08925 0.00496 9.17 1059 4.35 1053 0.10030 0.00491 1.13 1072 4.74 1067
2 0.08956 0.00497 5.70 1059 2.71 1053 0.10059 0.00492 1.17 1072 4.92 1067
cg11298343 19 41306150 EGLN2 1 0.02036 0.00201 1.94 1022 3.53 1017 0.01410 0.00141 5.42 1022 6.36 1017
2 0.02070 0.00199 1.37 1023 3.25 1018 0.01402 0.00140 5.30 1022 7.42 1017
cg10585486 19 41304133 EGLN2 1 0.00901 0.00089 2.23 1022 3.53 1017 0.01349 0.00130 1.47 1023 3.09 1018
2 0.00902 0.00089 2.19 1022 3.47 1017 0.01347 0.00130 2.25 1023 4.72 1018
cg24958765 19 41283667 RAB4B 1 0.00235 0.00031 1.17 1013 9.27 109 0.00427 0.00075 2.02 108 1.06 103
2 0.00237 0.00031 1.02 1013 8.06 109 0.00433 0.00075 1.26 108 6.62 104
cg13791183 19 41316697 CYP2A6-
AK097370
1 0.01244 0.00209 4.23 109 2.51 104 NA
2 0.01255 0.00209 3.28 109 1.94 104
cg25923056 19 41306455 EGLN2 1 0.00952 0.00177 1.00 107 5.30 103 0.01153 0.00141 1.50 1015 1.05 1010
2 0.00985 0.00175 2.54 108 1.34 103 0.01140 0.00141 2.73 1015 1.91 1010
b: Regression coefficient estimates from linear regression model regressing DNA methylation levels on indicated SNPs. In Model 1 coefficients are corrected for sex,
age, technical covariates and different white blood cellular proportions. In Model 2 coefficients are additionally adjusted for current smoking and pack-years smoked.
SE: standard error of the effect, P: P-value of the significance, FDR: False discovery rate value. NA: Not available in the replication dataset.
Figure 2. Association of the rs7937 with DNA methylation across the genome. In circles are represented all CpGs throughout the genome. X-axis shows chromosome
locations; Y-axis shows negative logarithm of the P-value of the associations of the SNP with each CpG site. Dotted line represents the significance threshold
(FDR< 0.05). (A) Discovery analysis; (B) Replication analysis.
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differential expression of ILMN_2354391 in EGLN2 in blood. In
further investigation, we performed the formal mediation anal-
ysis where we show (Table 5) that 42% of the association
between rs7937 and EGLN2 expression is indeed mediated
through cg11298343 (P¼ 0.04).
Moreover, genome-wide eQTL analysis of rs7937 in lung tis-
sue of 1087 participants from the Lung expression quantitative
loci mapping study (LES), showed significant associations
(P< 1.36 106) with 5 probes in the same region [in cis;
AK097370(EGLN2), NUMBL] and other chromosomes [in trans;
LOC101929709, DNMT3A and PAK2] (Table 6). In all cases, except
one (LOC101929709 at chromosome 8), the T allele of rs7937 was
consistently associated with decreased expression of the genes
in lung tissue (Table 6, Supplementary Material, Fig. S2).
Discussion
Our study shows that the rs7937 in 19q13.2 is associated with
differential blood DNA methylation of 4 CpG sites located in the
EGLN2 in the discovery and replication cohort. The COPD risk
allele (T) is associated with lower DNA methylation at these
sites. These relationships are independent of smoking and of
COPD. We further show that DNA methylation in blood at
cg11298343 (EGLN2) is associated with COPD, and remains nomi-
nally significant after adjusting for smoking. Finally, rs7937 is
associated with differential expression in blood of EGLN2, 42%
explained by EGLN2 DNA methylation at site cg11298343, and in
lung tissue of NUMBL, AK097370 (EGLN2), LOC101929709,
DNMT3A and PAK2.
EGLN2 is coding prolyl hydroxylase domain-containing pro-
tein 1 (PHD1) which regulates posttranscriptional modifications
of hypoxia induced factor (HIF), a transcriptional complex
involved in oxygen homeostasis. At normal oxygen levels, the
alpha subunit of HIF is targeted for degradation by PHD1, which
is an essential component of the pathway through which cells
sense oxygen (24), is also known to be involved in activation of
inflammatory and immune genes, including those implicated in
COPD (25). Furthermore, read-through transcription exists
between this gene and the upstream RAB4B, and together they
were shown to be involved in invasive lung cancer (26).
Our study of DNA methylation in blood replicates the find-
ings of a study on meQTLs in blood across the human life
course: during pregnancy, at birth, childhood, adolescence and
middle age (27) which reported three (cg10585486, cg11298343,
cg25923056) out of our four replicated CpGs. We additionally
report a novel finding in association with rs7937, our top hit,
cg21653913. Interestingly, they report differential DNA methyla-
tion at cg11298343 to be associated with rs7937 at all five time
points. In the present study, we now show that rs7937 is also
associated with cg11298343 in our elderly sample, the age cate-
gory at highest risk for developing COPD. This finding goes in
line with our hypothesis that the life-long change in the DNA
methylation is involved in the pathogenesis and onset of COPD
in older age, rather than the other way around. However, fur-
ther longitudinal studies are needed, testing this hypothesis in
lung tissue.
In line with our findings, rs7937 has previously been associ-
ated with differential expression of EGLN2 in blood (28). Having
both DNA methylation and transcription data available, we
could further test whether the relation of rs7937 and EGLN2
Table 3. Association of DNA methylation at significant CpG sites in
19q13.2, with COPD and FEV1/FVC ratio – meta-analysis results
Trait CpG N Model b SE P
COPD cg21653913 1339 1 0.084 0.711 0.906
2 0.175 0.738 0.812
cg11298343 1339 1 7.080 2.163 0.001
2 4.924 2.254 0.029
cg10585486 1339 1 2.215 3.657 0.545
2 3.110 3.811 0.415
cg25923056 1339 1 0.368 2.153 0.864
2 1.551 2.255 0.492
FEV1/FVC cg21653913 1188 1 0.008 0.020 0.676
2 0.017 0.020 0.382
cg11298343 1188 1 0.138 0.065 0.035
2 0.047 0.064 0.464
cg10585486 1188 1 0.096 0.093 0.304
2 0.094 0.090 0.299
cg25923056 1188 1 0.021 0.064 0.743
2 0.098 0.062 0.114
N: number of participants in the meta-analysis; Model 1 is adjusted for age, sex,
technical covariates and different white blood cellular proportions, Model 2 is
additionally adjusted for smoking; b: Regression coefficient estimates from
logistic/linear regression models; SE: standard error of the effect; P: P-value of
the significance. In bold: nominally significant associations.
Table 4. Association of rs7937 with transcriptome-wide gene expression in blood (N¼ 721)
SNP A1 A2 Probe Chr Position (GRCh37/hg19) Gene Model b SE P FDR
rs7937 T C NM_080732.1 19 46006086-46006135 EGLN2 1 0.0635 0.0109 9.29 109 0.000197
2 0.0577 0.0120 1.88 106 0.039942
A1: effect allele (tested allele), A2: alternative allele, Chr: chromosome of the probe, Model 1 is adjusted for age, sex, current smoking, technical covariates and different
white blood cellular proportions, Model 2 is additionally adjusted for cg11298343; b: Regression coefficient estimates from linear regression models regressing gene
expression on indicated SNP, SE: standard error, P: P-value of the significance, FDR: False discovery rate value.
Table 5. Mediation of the rs7937-EGLN2 expression association
through cg11298343 (N¼ 721)
Estimate 95%CI Lower 95%CI Upper P-value
ACME 0.02 0.005 0.032 0.01
ADE 0.02 0.014 0.068 0.22
Total Effect 0.04 0.005 0.080 0.03
Proportion Mediated 0.42 0.058 1.995 0.04
ACME: average causal mediation effect by DNA methylation at cg11298343; ADE:
average direct effect of rs7937 on EGLN2 expression; Total: total effect rs7937 on
EGLN2 expression; Proportion Mediated: proportion of the association between
rs7937 and EGLN2 expression, explained by methylation at cg11298343;
Regression models adjusted for sex, age, current smoking, pack-years, technical
variance and estimated blood cell composition; In bold: significant results with
P-value <0.05.
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expression could be explained by DNA methylation levels of
EGLN2 at cg11298343 site. We show for the first time that in
blood there is indeed a mediation of 42% through the DNA
methylation at cg11298343, confirming our hypothesis. We
report two novel findings in this region in the lung tissue. We
found that rs7937 is involved in expression of AK097370 in lung
tissue, a DNA clone in the proximity of EGLN2, as well as with
NUMBL. NUMBL is known as a negative regulator of NF-kappa-B
signaling pathway in neurons (29) and was also found to be
expressed in the lungs in the GTEx database (30). The associa-
tion between rs7937 and gene expression in the same dataset
has been tested earlier by Lamontagne et al. (31) but no signifi-
cant results were reported. In the present study, using a more
powerful meta-analysis approach, rs7937 was associated with
two loci in the region (NUMBL and AK097370, close to EGLN2)
and three more loci in other chromosomes (LOC101929709,
DNMT3A and PAK2). Taken together, our findings raise the
hypothesis that the genetic effect of rs7937 on COPD might be
mediated by DNA methylation at cg11298343 and subsequent
alteration of expression of EGLN2 and other genes in this region,
such as NUMBL. We show this in blood but further formal medi-
ation analyses in lung tissue are needed to confirm this hypoth-
esis, requiring the assembly of a large dataset of lung tissue
characterized for genetic, epigenetic and transcriptomic data.
Furthermore, we have found significant associations in
lungs of rs7937 in trans, i.e. with the expression of genes on
other chromosomes. These effects include differential expres-
sion of PAK2 (chromosome 3), DNMT3A (chromosome 2) and
long non-coding RNA on chromosome 8. The protein encoded
by PAK2 gene is activated by proteolytic cleavage during
caspase-mediated apoptosis, and may play a role in regulating
the apoptotic events in the dying cell (32). DNMT3A is the gene
encoding the DNA methyltransferase which plays a key role in
de novo methylation. This may imply that rs7937 is involved in
the pathogenesis of COPD through differential DNA methylation
and regulation of expression throughout the genome, again ask-
ing for further research of DNA methylation.
The strength of our analysis is the use of large and unique
samples of patients whose genetic, epigenetic and transcrip-
tomic characteristics were assessed in detail. However, a limita-
tion of our study is the use of blood tissue for the assessment of
DNA methylation and gene expression. Nevertheless, our find-
ings regarding the role of the genetic variants in blood corrobo-
rate with the changes in the transcriptome in lung tissue. It has
been shown that blood can be used to evaluate methylation
changes related to COPD and smoking, as the disease induces
systemic changes associated with elevated markers of systemic
inflammation in blood (25). A second limitation of our study is
that we cannot distinguish the expression in lung parenchymal
Table 6. Association of rs7937 with transcriptome-wide gene expression in lung tissue (N¼ 1087)
SNP A1 A2 Probe Chr Position (GRCh37/hg19) Annotation b SE P FDR
rs7937 T C NM_004756 19 40665906-40690658 NUMBL 0.099 0.013 4.39 1015 1.17 1011
BC037804 19 40808443-40810818 AK097370 (EGLN2) 0.077 0.012 3.77 1010 1.01 106
BX330016 8 89720919-89724906 LOC101929709 0.049 0.011 6.15 106 0.016
AK025230 2 25233434-25246179 DNMT3A 0.028 0.006 8.00 106 0.021
BQ445924 3 196829093-196830253 PAK2 0.028 0.006 1.36 105 0.036
A1: effect allele (tested allele), A2: alternative allele, b: Regression coefficient estimates from linear regression models regressing gene expression on indicated SNP, SE:
standard error, P: P-value of the significance, FDR: False discovery rate value.
Figure 3. Region plot of chromosome 19q13.2 with significant SNP-CpG associations. The circles represent SNP-CpG associations; X-axis shows all genes in the region;
Y-axis shows negative logarithm of the P-values of the associations of CpGs with the SNP. Crossed circles represent the non-replicated associations.
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tissue, which comprises multiple cell types. It may be specu-
lated that expression of only distinct cells is affected by rs7939.
If this is the case, the most likely effect is that the power of our
study is reduced, but has not biased our findings in the sense of
generating false positives. However, although eQTLs are fre-
quently cell- and tissue-specific (33), many eQTLs are also
shared across tissues (34). Finally, the number of patients with
COPD and spirometry measures were limited, which may have
compromised the power of the study. Nevertheless, we
observed significant findings that are relevant for COPD.
In conclusion, our findings suggest that genetic variations
underlying EGLN2 methylation contribute to the risk of devel-
oping COPD. This finding adds insight into how genetic var-
iants are involved in the pathogenesis of COPD, through
differential DNA methylation and regulation of expression,
irrespective of smoking. Future integrative studies involving
genetics, epigenetics and transcriptomics in lung tissue are
crucial to elucidate the molecular mechanisms behind COPD
genetic susceptibility and to translate the findings to clinical
care and prevention. This may lead to an increased specificity
and sensitivity of diagnostic and prognostic tools. In addition,
novel DNA methylation loci may be used as a target for future
drug design in COPD. While smoking cessation is shown to be
a useful prevention tool for disease risk and mortality reduc-
tion, DNA methylation loci independent of smoking may be
used as a target for a more personalized and focused treat-
ment approach.
Materials and Methods
Study population
For our analyses in blood we used two independent subsets of
participants from the RS (23). The full discovery set for meQTL
analysis was comprised of 724 participants with full genomic
and epigenetic data, while replication set included 766 partici-
pants. The replication subset is part of the Biobanking and
Biomolecular Resources Research Infrastructure for The
Netherlands (BBMRI-NL), BIOS (Biobank-based Integrative
Omics Studies) project (35). RS has been approved by the
Medical Ethics Committee of the Erasmus MC and by the
Ministry of Health, Welfare and Sport of the Netherlands, imple-
menting the Population Studies Act: Rotterdam Study. All par-
ticipants provided written informed consent to participate in
the study and to obtain information from their treating physi-
cians. The detailed information on our samples can be found in
Supplementary Material.
Spirometry measures and COPD diagnosis
From the initial full datasets for meQTL analysis (ndiscovery¼724,
nreplication¼766), after excluding participants with asthma, we
used data from 655 participants in the discovery and 684 partici-
pants in the replication cohort for the association analyses with
COPD. COPD diagnosis was defined as pre-bronchodilator FEV1/
FVC< 0.7. More detailed information can be found in
Supplementary Material.
COPD SNPs selection
Using the GWAS catalog (36) on 15 January 2017, we performed
a search with the term ‘19q13.2’, additionally applying filters for
the P-value 5 108 and for the trait to include term ‘Chronic
obstructive pulmonary disease’. One GWAS study passed these
filtering criteria, and reported the top SNP, rs7937-T
(NC_000019.10: g.40796801C>T), to be associated with COPD
(OR¼ 1.37) (9). We used this SNP to perform all analyses in our
study.
Genotyping in RS
Genotyping was performed using 610K and 660K Illumina arrays
for which whole blood genomic DNA was used. Detailed infor-
mation can be found in Supplementary Material. Imputation
was done using 1000 Genomes (1KG) phase I v3 reference panel,
with measured genotypes that had minor allele frequencies
(MAF)>1%, performed with MacH software and Minimac imple-
mentation. We extracted dosages of rs7937 [risk allele T, allele
frequency¼ 0.54], from RS imputed data using DatABEL library
of R-package (37).
DNAmethylation array in RS
We used Illumina Infinium Human Methylation 450K array to
quantify DNA methylation levels across the genome from whole
blood in RS. The detailed QC and normalization criteria can be
found in the Supplementary Material. Ultimately, after the QC
and normalization steps our discovery set included 724
Caucasian participants and 463 456 probes, while the replication
set included 766 Caucasian participants and 419 936 probes.
RNA array in blood in RS
In the discovery sample, we used the same blood samples at
baseline to isolate RNA, which we hybridized to Illumina
Whole-Genome Expression Beadchips Human HT-12 v4 array.
Raw probe intensities were quantile-normalized and 2-log
transformed and controlled for quality as described elsewhere
(28). After all normalization and QC steps the sample consisted
of 21 238 probes in 721 participants with available full data on
SNP and RNA arrays and all covariates.
RNA array in lung tissue
Gene expression was quantified using lung tissue samples
obtained from patients that underwent lung resection surgery
at three facilities participating in the LES: University of
Groningen (GRN), Laval University (Laval) and University of
British Columbia (UBC) (38). Illumina Human1M-Duo BeadChip
arrays were used for genotyping, and a custom Affymetrix
microarray (GPL10379) for gene expression profiling. The final
dataset for the eQTL analysis consisted of 1087 subjects. More
detailed information can be found in Supplementary Material.
Statistical analyses
meQTL analysis
We performed EWAS in the discovery cohort using linear
regression analysis with rs7937-T as independent variable and
DNA methylation sites as dependent variable. We fitted two
models; first adjusted for age, sex, technical covariates to cor-
rect for batch effects (array number and position on array) and
the estimated white blood cell counts (39) (including mono-
cytes, T-lymphocytes: CD4 and CD8, B-lymphocytes, natural
killer cells, neutrophils and eosinophils) (Model 1); and second,
for significant sites additionally adjusted for current smoking
and pack-years smoked (Model 2). We used the FDR< 0.05 as an
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epigenome-wide significance threshold (40). Significant sites
from Model 1 were then tested for association in the replication
cohort using the same models as in the discovery. Since the
19q13.2 region was also implicated in smoking behavior, we
also tested significant CpG sites in a third model including
‘rs7937 smoking’ interaction term to assess possible interac-
tion between rs7937 and smoking (for both current smoking and
pack-years smoked), in the discovery and replication cohorts. In
addition, for the significant sites we used another model addi-
tionally adjusted for COPD status which we compared with the
Model 1 in attempt to further elucidate the direction of the
effect between DNA methylation and COPD.
COPD and FEV1/FVC analysis
To test if the significantly associated methylation sites are also
associated with the lung phenotypes, we performed logistic and
linear regression analyses with COPD and FEV1/FVC ratio,
respectively as dependent variables and DNA methylation as
independent variable. In the first model we adjusted for age,
sex, technical covariates and estimated white blood cell counts
and additionally for current smoking and pack-years smoked in
the second model, in both the discovery and the replication
cohort. Results from the two cohorts were meta-analysed using
fixed effect models with ‘rmeta’ package in R (41). Bonferroni
correction was applied to adjust for multiple testing. In addi-
tion, for the significant sites we used another model addition-
ally adjusted for rs7937 which we compared with the first model
in attempt to further elucidate the direction of the effect
between DNA methylation and COPD.
Blood eQTL analysis
In the discovery cohort, we tested whether rs7937 is associated
with differential expression in the whole blood. We used linear
regression analysis with rs7937 as independent variable and
genome-wide normalized gene expression as dependent varia-
ble. For this analysis, we used model adjusted for age, sex, cur-
rent smoking, technical batch effects (plate ID and RNA quality)
and white blood cell counts (lymphocytes, monocytes and gran-
ulocytes). For significant (FDR< 0.05) probes, the second model
was additionally adjusted for significant DNA methylation
levels.
Mediation analysis
We have performed formal mediation analysis using the boot-
strapping method in the ‘mediation’ package in R (42), to assess
the potential mediator role of significant DNA methylation in
the SNP-expression association. One thousand bootstraps were
run to estimate the confidence intervals (43). We used models
adjusted for age, sex, current smoking, pack-years, expression
technical batch effects (plate ID and RNA quality), methylation
technical batch effects (position on array and array number)
and estimated blood cell composition.
Lung eQTL analysis
To test if the SNP rs7937 is associated (FDR< 0.05) with differen-
tial expression in lung tissue in LES, we performed a genome-
wide linear regression analysis with the SNP as the independent
variable and 2-log transformed gene expression levels as
dependent variable. This analysis was performed for each of the
three participating cohorts (GRN, Laval and UBC) separately,
adjusted for lung disease status, age, sex, smoking status and
cohort-specific principal components (PCs). The inverse-
variance weighted fixed effect meta-analysis of the results
obtained from the three cohorts was performed with ‘rmeta’
package in R software. The detailed overview of the fitted mod-
els can be found in the Supplementary Material.
Supplementary Material
Supplementary Material is available at HMG online.
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